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Abstract 
Non-infectious inhaled microbial particles can cause illness by triggering an inappropriate 
immunological response. From the pathogenic point of view these illnesses can be seen to be 
related to on one hand autoimmune diseases and on the other infectious diseases.  
In this review three such illnesses are discussed in some detail. Hypersensitivity pneumonitis 
(HP) is the best known of these illnesses and it has also been widely studied in animal models 
and clinically. In contrast to HP Pulmonary mycotoxicosis (PM) is not considered to involve 
immunological memory, it is an acute self-limiting condition is caused by an immediate "toxic" 
effect. Damp building related illness (DBRI) is a controversial and from a diagnostic point 
poorly defined entity that is however causing, or attributed to cause, much more morbidity 
than the two other diseases.  
In the recent decade there has been a shift in the focus of immunology from the lymphocyte 
centered, adaptive immunity towards innate immunity. The archetypal cell in innate immunity 
is the macrophage although many other cell types participate. Innate immunity relies on a 
limited number of germline coded receptors for the recognition of pathogens and signs of 
cellular damage. The focus on innate immunity has opened new paths for the understanding of 
many chronic inflammatory diseases. The purpose of this review is to discuss the impact of 
some recent studies, that include aspects concerning innate immunity, on our understanding 
of the pathogenesis of inflammatory diseases associated with exposure to inhaled microbial 
matter. 
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Innate Immunity and the inflammasome 
Vertebrates have a two-tiered system to defend 
themselves  against  pathogen.  The  innate  immunity 
system is the first one to be activated by pathogens 
and  it  is  for  the  most  part  sufficient  on  its  own, 
however  when  the  strength  of  the  challenge  from 
pathogens  reaches  an  critical  threshold  the  innate 
immunity triggers the adaptive immunity system. The 
adaptive immunity relies on receptors on the B and T 
cells generated through somatic gene rearrangements 
and hypermutation allowing the adaptive immunity 
to specifically recognize any type of microorganisms. 
In  the  innate  system  microbes  are  recognized  by  a 
limited  number  of  germline  coded  receptors  called 
pattern recognition receptors (PRRs) [1-3]. The PRRs 
recognize structures called pathogen-associated mo-
lecular patterns (PAMPs) that are common to many 
pathogens. The PAMPs are usually essential for the 
viability of the microbes, thus minimizing the possi-
bilities of the pathogens to avoid detection by simply 
altering the PAMP. Substances recognized by PRRs 
include  cell  wall  components  peptidoglycan,  lipo-
polysaccharide and bacterial DNA. The PRRs include Int. J. Biol. Sci. 2011, 7 
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Toll-like  receptors  (TLRs),  NOD-  of  like  receptors 
(NLRs), C-type lectin receptors, and RIG-I like recep-
tors [4, 5]. The model based on PAMP recognition was 
proposed by Charles Janeway Jr [6]. It was soon real-
ized that an additional element was required to ex-
plain why non- pathogenic bacteria did not cause ac-
tivation  of  the  innate  immunity.  Polly  Matzinger 
suggested that the innate immunity system in addi-
tion relies on the recognition of cell injury by danger 
associated  molecular  patterns  (DAMPs)  [7].  Subse-
quently  it  has  indeed  been  shown  that  that  among 
others ATP, mammalian double stranded DNA and 
uric acid crystals activate an inflammatory response 
[8].  
The receptors engaged then induce the synthesis 
of a spectrum of inflammatory mediators. Central for 
most  inflammatory  reactions  is  the  production  of 
IL-1 and a related protein IL-18, both are produced 
in  the  cytosol  as  inactive  precursor  forms.  IL-18  is 
present in resting cells while IL-1 precursor is only 
produced in activated cells [9]. The formation of bio-
active secreted 17- or 18kDa forms of IL-1 and IL-18 
is dependent on the proteolytic activity of a caspase 
which is activated in molecular platforms named in-
flammasomes  [10].  Eleven  caspases  are  presently 
known  in  humans,  these  are  divided  into 
pro-inflammatory caspases (caspases 1, 4, and 5) and 
apoptotic caspases (caspases 2, 3, and 6-10) [11, 12]. 
Inflammasomes  can  be  described  as  multiprotein 
complexes that link the recognition of cellular damage 
by  members  of  the  Nod-like  receptor  (NLR)  to  the 
processing and release of IL-1 and IL-18. NLR:s are 
cytosolic  intracellular  PRRs  that  recognize  PAMPS 
and endogenous ligands. In addition to activating the 
inflammasome NLR:s can activate the NFB pathway 
[13].  In  general  there  is  a  surprising  tendency  for 
DAMP:s and PAMPS to use similar molecular path-
ways. This is apparent with HSP:s (heat shock pro-
teins)  that  are  endogenous  damage  associated  pro-
teins  recognized  by  the  typically  PAMP  related 
TLR-MyD88-NFB  pathway  [14].  Another  DAMP 
released by damaged cells is HMGB-1 which is also 
extensively recognized by TLR:s [15]. 
Central  components  of  the  inflammasome  are 
NLRs, the pyrin domain (PYD) and caspase recruit-
ment  domain  (CARD)  containing  adaptor  protein 
ASC  (apoptosis-associated  speck-like  protein  con-
taining a CARD) and caspase-1. 
The activation of the inflammasome is initiated 
by the recognition of intracellular PAMPS or signs of 
stress or danger from the hosts, DAMPS, by a cyto-
solic  NLR.  The  NLRS  undergo  ATP-dependent  oli-
gomerization and recruit ASC by PYD-PYD interac-
tion. Subsequently, caspase 1 is recruited through the 
CARD of ASC.   
NLRP3 (NLR pyrin domain containing 3,) and 
the inflammasome it is a part of has been linked to a 
number  of  inflammatory  diseases.  These  include 
contact hypersensitivity, sunburn, essential hyperten-
sion,  gout  and  pseudogout.  NLRP3  is  activated  by 
exogenous and endogenous ligands. Exogenous lig-
ands include microbial ligands (PAMP)s such as the 
bacterial product MDP (muramyl dipeptide) bacterial 
and viral RNA. Endogenous ligands (PAMPS )include 
uric  acid  (monosodium  urate  crystals),  calcium  py-
rophosphate crystals, NLRP3 in combination with the 
P2X7 receptors take part in recognizing extracellular 
ATP[3]. Fig 1 shows a schematic representation of the 
activation of IL-1 production by LPS as an example 
of a PAMP and uric acid as an example of a DAMP. 
The  complexity  of  inflammatory  regulation  is 
understandable from the point of view that there are 
severe risks for the organism both from a lack of suf-
ficient response to a pathogen or an exaggerated re-
sponse  to  a  pathogen.  There  are  thus  two  separate 
major  control  points  for  the  production  of  IL-1, 
transcription is initiated by the recognition of patho-
gen (and some DAMPS) by PRR:s and secretion of the 
active  form  is  initiated  by  activation  of  the  inflam-
masome by DAMPS and intracellular PAMPS [16]. 
Inflammatory diseases in the airways caused 
by exposure to microbial substances 
Pulmonary mycotoxicosis (PM, organic dust syn-
drome) is an acute febrile respiratory illness associ-
ated  with  the  exposure  to  high  levels  of  microbial 
matter. Typically the exposure occurs in an agricul-
tural  context,  but  every  occupation  associated  with 
the handling of organic material possesses some risk. 
PM does not depend on immunological sensitization, 
so it can occur during or immediately after the first 
exposure. Airborne bacterial and fungal spore counts 
are mostly higher than those associated with HP [17]. 
In cases of heavy exposure to organic dust most of the 
exposed become ill. However in conditions of lighter 
exposure the proportion individuals affected can be 
very  small.  The  clinical  picture  is  an  influenza  like 
reaction with 70-95 % of affected individuals experi-
encing shivering with fever and myalgias. Approxi-
mately half will experience chest tightness and cough, 
headache and nausea is also fairly common. Irritation 
of  eyes,  nose  and  throat  has  also  been  reported. 
Symptoms will occur 4-12 hours after the start of the 
exposure but they rarely persist beyond 1 or 2 days. 
Continuing  the  exposure  will  often  decrease  the 
symptoms, in contrast to the other illnesses discussed 
in this review. PM is characterized by macrophages Int. J. Biol. Sci. 2011, 7 
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and neutrophiles in the BAL fluid [18] and an inter-
stitial and intra-alveolar neutrophilic and macrophage 
infiltrate  associated  with  bronchiolitis  [18],  In  some 
cases lymphocytosis has been reported at later stag-
es[19, 20]. In general there is not much ongoing re-
search activity in this disease, probably because it is a 
relatively benign and self-limiting condition. In addi-
tion the incidence of PM is probably decreasing be-
cause of changing work methods. In a study on Swe-
dish farmers that had experienced PM it was a single 
event for almost half of farmers studied while the rest 
had two or more attacks often several years apart[21]. 
Some clinical features of PM as well as HP and DBRI 
are shown in table 1. 
 
 
 
Fig 1 Example of IL-1production activation after ligation of a TLR receptorby LPS and activation of the NALP3 inflam-
masome by uric acid.  
 
 
 
Table 1: Some features of illnesses attributed to the exposure of microbial particles 
 
 
 
Pulmonary 
mycotoxicosis 
 
 
DBRI 
 
 
HP 
 
Exposures 
required 
 
 
Single 
 
Repeated (see text) 
 
Repeated 
Consequence of 
re-exposure 
Activity of illness can decrease  Activity of illness increases  Activity of illness  
increases 
 
Susceptibility of the 
exposed 
 
All of the exposed can develop 
illness 
 
Part of the exposed 
develop illness (see text) 
 
Part of the exposed  
develop illness 
 
Cells increased 
in BAL 
 
neutrophils macrophages  
lymphocytes 
 
 
lymphocytes,  
macrophages ? 
 
lymphocytes,  
macrophages  
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Hypersensitivity pneumonitis (HP), also known as 
allergic alveolitis, is caused by an exposure to a wide 
range of thermophilic bacteria, molds, other bacteria 
and bacterial products, amoebae, and some chemicals. 
In some cases HP is caused by a reaction to a single 
environmental agent while in other cases a mixture of 
microbes  is  required  [22].  Only  a  small  portion 
(1%-15%) [22, 23], of those exposed develop HP. The 
particles causing HP are generally of organic origin 
and  their  size  is  suitable  for  reaching  the  alveolar 
space in lungs. The particles usually have adjuvant 
activity, interestingly many of the animal models for 
HP is dependent on adjuvant (typically freunds com-
plete adjuvant CFA) for costimulation [23]. Clinically 
HP is divided in acute, subacute and chronic forms, 
[18]. The symptoms in the acute form are reminiscent 
of pulmonary mycotoxicosis while main symptoms in 
the  subacute  and  chronic  forms  are  shortness  of 
breath. Lymphocytosis, often accompanied by an in-
crease  in  macrophages[24]  is  seen  in  BAL  (bron-
choalveolar lavage) [25], the earliest lymphocytes are 
CD4+, later the proportion of CD8+ cells increase [22]. 
Histologically  HP  is  characterized  by  a  temporally 
uniform inflammation of the interstitial portion of the 
lung tissue. Early in the course this process is distrib-
uted  around  respiratory  bronchioles.  Lymphocytes 
comprise  the  majority  of  infiltrating  cells;  scattered 
plump  macrophages  in  clusters  around  bronchioles 
are also seen. Small non-necrotizing granulomas are 
found  in  two-thirds  of  the  cases.  The  granulomas 
contain a mixture of epitheloid macrophages, multi-
nucleated giant cells and lymphocytes [18]. Repeat or 
continuous  exposures  will  cause  progression  of  the 
disease with increasing deterioration of lung function 
and fibrotic changes in the lungs.  
The patients have often IgG against antigens on 
the microbes they are exposed to, this is however not 
specific for patients with HP and these antibodies can 
also be seen in exposed individuals without HP [17]. 
Earlier the formation of immune complexes with this 
IgG was considered to be a central part of the patho-
genesis.  However  the  current  view  is  that  HP  is 
caused  by  cytotoxic  delayed  hypersensitivity  lym-
phocytes  [22].  Some  recent  results  suggest  that  the 
development  of  chronic  HP  is  associated  with  the 
skewing of CD4 and CD8 cells toward a Th2 pheno-
type [26]. It has been suggested that the mechanisms 
ultimately leading to lung fibrosis are similar to those 
(as yet poorly known) in interstitial lung diseases in 
rheumatoid arthritis and idiopathic pulmonary fibro-
sis [22, 27, 28]. 
In animal models the earliest cellular event is an 
activation of macrophages followed by an influx of 
neutrophiles and lymphocytes [29]. Normal alveolar 
macrophages (AM) have a low expression of the co 
stimulatory  molecule  CD80/CD86  and  and  a  poor 
capacity  to  function  as  antigen  presenting  cells 
(APC:s),  In  HP  the  macrophages  are  activated  and 
express increased levels of CD80 and CD86 [30-33].  
CD 80 and CD86 bind to CD28 and CD 152 (earlier 
called CTL4) present on the surface of T-cells. CD 28 is 
constitutively  expressed  on  the  surface  of  T-cells 
while CD152 is not expressed on resting T-cells but it 
is upregulated during cell cycle progression. The re-
lationship between CD28 and CD152 is complex [34]. 
In short CD28 promotes T-cell activation while CD152 
appears to restrict T-cell activation. Studies in mouse 
models have shown that a blockade of co stimulation 
by CTLA4 -Ig inhibits lung inflammation in the mu-
rine model for HP, both the amounts of lymphocytes 
and macrophages in the BAL fluid decrease [35]. In 
mice models for HP the mice develop tolerance [36] if 
the exposure is prolonged.  
Sick building syndrome (SBS) was first described in 
1982 [37], a major, but not the only cause, for SBS is 
dampness  in  buildings.  Damp  building  related  illness 
(DBRI)  refers  to  those  cases  of  SBS  associated  with 
water damage in dwellings or workplaces. There is a 
consensus for the association of dampness with health 
effects, [38-40]. By definition DBRI include both HP 
and pulmonary mycotoxicosis if they are caused by 
damp buildings. It is however rare for damp build-
ings to cause HP and still rarer for them to cause a 
full-fledged  pulmonary  mycotoxicosis.  The  typical 
DBRI is associated with a prolonged exposure to wa-
ter damaged buildings, usually only a portion of the 
exposed develop symptoms [41, 42]. As in the case of 
allergic  alveolitis  continuation  of  the  exposure  will 
usually worsen the symptoms. There is currently no 
well-defined diagnostic criteria for the great majority 
of DBRI:s. The symptoms tend to be quite diverse but 
include  fever,  myalgias,  cough  and  headaches 
somewhat  reminiscent  of  PM.  Recently  we  have 
shown that exposure to water damage in buildings is 
associated with an increase in lymphocytes in BAL, 
this is similar to findings in HP and some cases of 
pulmonary mycotoxicosis, although the there was no 
change in the CD4/CD8 ratio in contrast to the in-
crease of CD8 cells usually seen in HP [43]. In this 
study the number of macrophages was also increased 
but the increase was not significant possibly because 
of a lag between the start of symptoms and the BAL 
procedure. 
Recent developments 
A  component  of  fungal  walls,  (1-3)-  -glucans 
have been shown to be recognized by the C-type lec-
tin dectin-1 [44]. In mice exposure to a (1-3)-  glu-Int. J. Biol. Sci. 2011, 7 
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can, curdlan has been shown to promote interleukin 
17 (IL-17) producing T helper cells (Th 17 cells) [45]. In 
humans it has been shown that candida albicans spe-
cific  memory  cells  have  a  Th17  phenotype  [46,  47]. 
IL-1 is known to be necessary for the production of 
Th17 cells [48] and it can also induce Il-23 and IL-6 
both  of  which  promote  the  formation  of  Th17  cells 
[47]. It has also been hypothesized that curdlan might 
support  Th17  development  because  of  its  ability  to 
preferentially  promote  IL-23  production.  More  re-
cently it has been shown in a mouse model of HP [49, 
50]  using  saccharopolyspora  rectivirgula  (SR)  that  im-
mune response is Th17 -polarized and that in absence 
of IL-17 receptor signaling or T cells the lung inflam-
mation  and  fibrosis  is  significantly  decreased.  It 
should be noted that SR is a thermophilic actinomy-
cete,  not  a  mold,  and  does  thus  not  contain 
1-3-glucan.  However,  production  of  IL-23  was  in-
creased and transcription of TLR 2,6 and dectin-1 was 
upregulated  in  the  mice  exposed  to  SR  [50].  TLR-6 
seems central for the IL-17 expression [51]. In humans 
many of the settings causing HP is associated with 
exposure to molds containing (1-3)--glucans.  
In  cell  culture  experiments  we  have  recently 
found that a group of toxins present in a number of 
molds (trichotecene mycotoxins) are able to cause an 
increased production of IL-1 and IL-18 by activating 
the  inflammasome  [52].  In  another  work  we  found 
that (1-3)--glucans, mentioned above in the context 
of Th17, in addition to being able induce the produc-
tion of IL-1 mRNA, is able to induce the activation of 
the inflammasome [53].  
Discussion 
The possible role of inflammasome activation in 
the pathogenesis of PM and other conditions which 
include a response to inhaled non-infectious particles 
poses  an  interesting  question.  As  described  earlier 
IL-1 production requires two distinct signals for ac-
tivation. The first signal, activating the transcription, 
is typically caused by PAMPS, abundant in the dusts 
causing PM. The second signal, activation of the in-
flammasome is however typically caused by danger 
signals related to tissue damage tissue. As the dust 
causing PM is not infectious there is presumably no 
primary tissue damage and thus no DAMP to activate 
the inflammasome. Recent work by Kankkunen et al 
[52,  53]  has  however  shown  on  other  hand  that 
trichotecane  mycotoxins  can  activate  the  inflam-
masome and on the other that -glucans can provide 
both  signals  for  the  activation  of  IL-1  production. 
Interestingly both the PRR recognizing glucan on 
the  surface  of  the  cells  (dectin-1)  and  the  inflam-
masome require the dectin-1/syk signalling pathway 
for activation.  Thus the same molecule can activate 
both the signals required for IL-1 production using 
in  part  the same  signal  transduction  pathway.  This 
finding seems related to the findings of convergence 
of  signalling  pathways  (between  DAMPS  and 
PAMPS)  in  the  activation  of  IL-1  production.  To-
gether  these  findings  seems  to  suggests  that  in  the 
activation of Il-1 production the central question is 
not what (DAMP or PAMP) but where (cell surface or 
cytosol) the activating molecule is. 
 If we thus consider pulmonary mycotoxicosis in 
the context of innate immunity, it is clear that there is 
an abundance of explanations to the macrophage ac-
tivation seen in this condition. High levels of various 
moulds  and  other  microbes  contain  both  pathogen 
related structures that PRR:s on the cells surface rec-
ognize and toxins and  -glucans that can provide a 
second signal activating the inflammasome.  
The first crucial events in the pathogenesis of HP 
is the formation of efficient APC:s. This requires an 
adjuvant  activity  of  the  microbial  components  in 
question [23]. The mechanism for the adjuvant activ-
ity can be explained by essentially identical mecha-
nisms  as  those  described  in  conjunction  with  PM. 
Consistent with this, increases in IL-1 level has been 
recorded in the BAL fluid of HP patients [23]. Studies 
on  mice  models  have  demonstrated  that  IL-1  has 
adjuvant properties [54], and that it is necessary for 
the production of antibodies against T-cell dependent 
antigens [55]. 
It is fairly easy to understand the pathogenesis of 
HP up to the point of production of IgG specific for an 
antigen present in the microbial matter in question. 
One of the unresolved questions in HP, is why only a 
small  proportion  of  those  exposed  and  producing 
specific IgG, go on to develop HP. A part of the ex-
planation could be associated with the repeated ex-
posures to antigen required in HP [56, 57]. IL-1 has 
been demonstrated to have a direct effect on memory 
T Cells [54, 58]. It has also been shown in a mouse 
model that IL-1 acts directly on CD4 T cells to en-
hance their antigen driven expansion and differentia-
tion,  especially  IL-17  and  IL-4  producing  cells.[48]. 
The engagement of the dectin receptor by the 1-3  
glucans  can  also  lead  to  a  Th17  polarization  of  the 
immunological  reaction  that  is,  at  least  in  mouse 
models a crucial step for the development HP. Thus it 
would  seem  possible  that  IL-1  production  is  in-
volved in the pathogenesis of HP both in the initial 
exposure  and  re-exposures.  A  further  obvious  re-
quirement for HP is a lack of tolerance [36].  Int. J. Biol. Sci. 2011, 7 
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Table 2: Key features in the development of allergic alveolitis. 
 
Feature  
 
Macrophage 
activation 
 
Lymphocyte 
activation 
 
 
No  developement 
of tolerance 
 
Formation  of:  Cytotoxic 
delayed  hypersensitivity 
lymhocytes? Th2 cells? 
 
Interstitial 
fibrosis 
Special properties of the 
cells  
 
CD80/86 high  
macrophages 
Th 17 cells       
 
 
DBRI is as already mentioned a poorly defined 
entity  with  few  objective  diagnostic  criteria.  In  this 
context it is of interest that in cases of HP in agricul-
tural settings, symptomless persons also exposed to 
the  dust  in  question  have  increased  levels  of  lym-
phocytes in their BAL fluid, as do people exposed to 
water damaged buildings [43]. To some extent DBRI 
can perhaps be considered to be related to HP with 
some  cases  including  features  of  pulmonary  myco-
toxicosis. However the types of microbial exposure in 
these diseases are quite divergent. In HP of farmer's 
lung type the patients have often been exposed to the 
antigens since childhood and the exposures are usu-
ally rather intense. In DBRI the exposure is usually 
not of as long duration and intensity as in farmer's 
lung. In any case the finding that microbial compo-
nents have the ability to activate the inflammasome 
and IL-1 production suggests a mechanism for the 
various phenomena associated with exposure to mi-
crobes in water damaged buildings.  
Conclusions  
The  airways  are  in  constant  contact  with 
non-infectious microbial particles and have evolved a 
tolerance for these. In PM the tolerance on the innate 
immunity level is breached by high concentrations of 
microbial particles. Interestingly in PM repeated ex-
posure  to  microbial  particles  sometimes  results  in 
some form tolerance at the innate immunity level. The 
development of HP probably requires a breakdown of 
tolerance  both  at  the  innate  and  specific  immunity 
level. It is however unquestionable that the inappro-
priate activation of specific immunity is causing the 
progress of HP. The pathogenesis of DBRI is largely 
unclear but the complexity of symptoms suggests a 
more complicated condition than that caused solely 
by the activation of innate immunity. The rather un-
structured clinical information available suggests that 
the  mechanisms  may  be  to  some  extent  similar  to 
those seen in HP.  
The  recent  advances  innate  immunity  and  its 
relationship  with  specific  immunity  suggest  many 
mechanisms  to  explain  the  phenomena  seen  in  ill-
nesses caused by inhaled microbial particles. Further 
studies,  especially  clinical  ones,  are  however  badly 
needed in order to determine if the explanations are 
valid. Much of the possible explanations are centered 
on the regulation of  Il-1 production. As  there is a 
receptor antagonist to IL-1 used as a drug for various 
inflammatory diseases (Anakinra) it can be possible to 
plan intervention studies on patients [59]. The same 
can  be  said about  CTL4  antagonists.  In  general  the 
patients  should  avoid  exposure  which  obviously 
makes studies meaningless; however there might be 
some groups where avoidance of exposure cannot be 
achieved. Another way  to approach the question is 
studies on the immunological response of cell samples 
from exposed patients [60]. Perhaps the best type of 
sample  for  this  purpose  is  bronchoalveolar  lavage 
(BAL) fluid. Studies on HP using BAL are relatively 
common but much less common for pulmonary my-
cotoxicosis  and  DBRI.  The  yield  from  the  standard 
BAL procedure is somewhat disappointing but vari-
ous advances in modern research techniques would 
make it possible to fully utilize the potential of BAL 
cells and fluids. 
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